Responses
1. From molecular pathways to clinical trials
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs
Compose a Response to This Article
Other responses
No responses have been published for this article.